Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

NCT04068597 is registered in ClinicalTrials.gov with CellCentric Ltd. as lead sponsor.

NCT NCT04068597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Lead sponsor
CellCentric Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 9, 2019
Completion date
March 31, 2027
Enrollment
250 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, haematological malignancy, higher-risk myelodysplastic syndrome, multiple myeloma, non hodgkin lymphoma, peripheral t cell lymphoma